FC Capital

Asia, Shanghai, China, Shanghai

Description

Fengchuan Capital is a private equity investment firm focused on the complete medical and pharmaceutical industry chain.

Investor Profile

FC Capital has made 6 investments, with 1 in the past 12 months and 33% as lead.

Stage Focus

Series A (67%)
Series C (17%)
Series B (17%)

Country Focus

United States (33%)
China (33%)
Switzerland (33%)

Industry Focus

Biotechnology
Health Care
Medical
Biopharma
Oncology
Pharmaceutical
Therapeutics
Business Development
Clinical Trials

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does FC Capital frequently co-invest with?

Bill & Melinda Gates Foundation

North America, New York, United States, New York

Co-Investments: 1

Shinhan Private Equity

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Co-Investments: 1

Bristol-Myers Squibb

North America, New York, United States, New York

Co-Investments: 1

Shinhan Capital

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Co-Investments: 1

SV Investment Corp

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Co-Investments: 1

Cathay Capital

Europe, Ile-de-France, France, Paris

Co-Investments: 1

QUAD Investment Management

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Co-Investments: 1

Partners Investment

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Co-Investments: 2

Rockspring Capital

North America, Texas, United States, Houston

Co-Investments: 1

PPF Group

Europe, Noord-Holland, The Netherlands, Amsterdam

Co-Investments: 2

What are some of recent deals done by FC Capital?

Degron Therapeutics

Shanghai, Shanghai, China

Degron Therapeutics is a platform company in discovery of molecular glue degraders for cancer treatment.

BiotechnologyHealth CareOncology

Series AJan 22, 2025

Lupeng Pharmaceutical

Guangzhou, Guangdong, China

Lupeng Pharmaceutical is a biotech company that focuses on the drug discovery and development of novel therapies for cancer treatment.

BiotechnologyHealth CareMedicalOncologyPharmaceutical

Series ANov 14, 2022

Amount Raised: $35,000,000

Harvest Integrated Research Organization

Excelsior, Minnesota, United States

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO).

BiopharmaBiotechnologyClinical TrialsMedicalPharmaceutical

Series AMar 18, 2022

Amount Raised: $1,572,030

Cellestia

Basel, Basel-Stadt, Switzerland

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.

BiopharmaBiotechnologyHealth CareTherapeutics

Series BDec 17, 2019

Amount Raised: $20,408,705

Vedanta Biosciences

Cambridge, Massachusetts, United States

Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.

BiotechnologyBusiness DevelopmentMedical

Series CSep 23, 2019

Amount Raised: $16,600,000

Cellestia

Basel, Basel-Stadt, Switzerland

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.

BiopharmaBiotechnologyHealth CareTherapeutics

Series ADec 19, 2018

Amount Raised: $20,120,502

FC Capital

Description

Investor Profile

Stage Focus

Country Focus

Industry Focus

Frequently Asked Questions

Who does FC Capital frequently co-invest with?

What are some of recent deals done by FC Capital?

Ready to Raise Capital?

Pages

Free tools